August 29, 2024
Hello team, Please find our social listening snapshot below for 08/16 - 08/29, along with a dashboard snapshot PDF attached.
LEO Pharma
Top LEO Pharma Company & Drug Discussions
- Company Mentions:
- LEO Pharma delivers 11% revenue growth in H1, with ADBRY revenue growing 85% during the period.
- TMB-001, LEO Pharma’s newly acquired candidate, comes up short in Phase III of its ASCEND trial for ichthyosis. MedWatch, PharmaPhorum, and The Pharma Letter also report on the news. In a follow-up article, MedWatch interviews LEO Pharma’s CEO, Christophe Bourdon, who expresses confidence in the company’s strategy despite the failed trial, highlighting delgocitinib as a promising candidate.
- MedWatch reports that Jan Van de Winkel has decided to step down from LEO Pharma’s board to focus on his responsibilities as CEO of Genmab.
- tralokinumab (ADBRY):
- Dermatology Times shares excerpts from its August print issue on its website, featuring ADBRY in an article titled “Is OX40 Inhibition the Next Game Changer for Atopic Dermatitis?”
- According to a new study, in patients with dupilumab-associated conjunctivitis, switching to tralokinumab led to complete resolution in a smaller percentage of cases compared to switching to JAK inhibitors.
- AcariaHealth, a national specialty pharmacy, announces its availability of ADBRY after partnering with LEO Pharma.
- On Reddit, an ADBRY patient shares a positive experience with the treatment, saying “ADBRY saved my life”, and “ADBRY was the best thing to happen to me. It’s expensive, but the people who help with insurance are amazing.”
- In other Reddit discussions, a patient’s caretaker asks for opinions on using low dose naltrexone for eczema, after ADBRY failed to improve symptoms. One patient is considering treating their dermatitis with CIBINQO instead of ADBRY, because ADBRY is not approved in their country.
- On TikTok, a male patient notices improvements to his AD symptoms after just two days of taking ADBRY. He also shares a similar post to Instagram.
- delgocitinib:
- 2 Minute Medicine reports on the DELTA 1 and DELTA 2 phase 3 trial results of delgocitinib, released earlier this month.
Other top Atopic Dermatitis (AD) & Chronic Hand Eczema (CHE) Discussions
- The New York Yankees’ Alex Verdugo appears to be affected by CHE and might start taking DUPIXENT shots, FOX Sports reports.
- Sanofi/Regeneron will present new DUPIXENT data at the European Respiratory Society (ERS) Congress 2024 in September.
- An Eczema influencer on YouTube interviews an HCP about the role filaggrin plays in eczema and topical steroid withdrawal (TSW), and how medications like DUPIXENT are helpful.
- According to an article in MedicalNewsToday that includes recent scientific research, eczema has links to breast implant illness (BII)
- On Reddit, many patients with severe eczema report positive experiences with DUPIXENT, and in another thread users prefer DUPIXENT over RINVOQ.
- In another thread on Reddit, users discuss treatment and remedies for CHE, including DUPIXENT, TerraOrigin, Triphala, and probiotics.
Dr. Reddy’s Laboratories
- Company Mentions:
- Dr. Reddy’s, Aurigene Pharmaceutical Services, and Stanford spinout Kainomyx announce a potential partnership for the joint development of an affordable anti-malarial drug.
- Dr. Reddy’s organizes a talk/Q&A for dermatologists in India.
- denosumab:
- According to a new study, incidence of medication-related osteonecrosis of the jaw (MRONJ) may be higher in patients with breast cancer with bone metastases, especially in those treated with denosumab.
- A case report is submitted for review on the use of Denosumab combined with microwave ablation excisional scraping for giant cell tumor of the thoracic spine.
- GlycoNex’s Phase I trial of its denosumab biosimilar, SPD8, reports positive results.
- COYA 302:
- Coya’s CEO highlights COYA 302 as a recent win for targeting “multiple, independent, and non-overlapping immune pathways simultaneously”.
- We did not find any US discussions about DRL_RI (rituximab biosimilar) or DRL_TC (tocilizumab biosimilar).
Paratek Pharmaceuticals
- We did not find any mentions about Paratek Pharmaceuticals.
- The most recent discussion we found about NUZYRA is from July, when Fierce Pharma reported on a post-marketing study of NUZYRA, demonstrating effectiveness and non-inferiority in treating CABP. The study is also mentioned in a post published this week on LinkedIn, summarizing drugs news from July.